Monitor NXT-41 FDA clearance decision in Q4 2026 and NXT-41x FDA submission; the $26M non-dilutive capital provides runway through early commercialization, but the widening operating loss and reliance on pipeline catalysts keep the risk profile elevated.
Drug in focus
ELUT drug pipeline →NXT-41
▲ Bullish Named in this press release- Impact
- Phase
- Filed/510(k) submission
- Time to market
- NXT-41 (base matrix) clearance decision expected Q4 2026 (within ~2 months). NXT-41x (antibiotic-eluting) clearance expected Q2 2027, with first full year of commercial launch targeted for 2028.
- Next catalyst
- None dated
What to watchWatch for the FDA 510(k) clearance decision on NXT-41 (base biologic matrix), expected by end of Q4 2026 (any day now through December). A clearance would validate the platform and clear the path for NXT-41x submission. The bigger catalyst is NXT-41x clearance expected Q2 2027, which would open the $1.5B breast reconstruction market. The company is fully funded through launch, removing near-term dilution risk. However, as a micro-cap single-product story, any regulatory delay or negative FDA feedback would hit the stock hard.
Price Chart
Executive Summary
Elutia reported Q3 2026 net sales of $1.1M (+20.4% YoY) but net loss from continuing operations widened to $6.5M from $1.0M a year ago, driven by higher R&D spending on NXT-41x. The company secured $26M in non-dilutive capital and plans to submit NXT-41x to the FDA in Q4 2026, with cash runway through the first full year of commercialization.
Key Financial Metrics
Key Facts
- Q3 2026 net sales $1.1M, up 20.4% YoY from $0.9M
- Net loss from continuing operations $6.5M vs $1.0M in Q3 2025
- R&D expense rose $1.9M to $3.0M, supporting NXT-41 and NXT-41x programs
- Adjusted gross margin (non-GAAP) improved to 85.5% from 81.3%
- Cash and equivalents $29.1M at Sep 30, 2026; plus $8M Boston Scientific holdback received Oct 1
- Company secured $26M in non-dilutive capital (Avenue loan, SimpliDerm sale, Boston Scientific escrow release)
- NXT-41x GLP rabbit study met performance endpoints; FDA submission planned in Q4 2026
- NXT-41 FDA clearance decision expected in Q4 2026
- Cardiovascular business strategic process on track for 2026
Financial Impact
Net loss from continuing operations $6.5M, net sales $1.1M, cash $29.1M plus $8M holdback
Risk Factors
- Net loss from continuing operations widened significantly to $6.5M from $1.0M YoY
- Company is pre-revenue on its lead pipeline (NXT-41x) and dependent on FDA clearances
- Cash burn rate may accelerate with R&D spending ahead of commercialization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3397149 |
Track record
7 reports on ELUT
Filters
- Nov 5, 202611d ago Press Release Neutral 4/10 Viewing No price data
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $0.8374 Now $0.8230 −1.72% settles Dec 7
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $0.8615 Now $0.8230 −4.47% settles Nov 20
- Jul 31, 202615w ago Press Release Neutral 1/10 Entry $0.8568 to $0.8800 Now $0.8230 −3.94% ▲ +2.71% −0.28% vs SPY
- Jun 16, 202621w ago 8-K Neutral 3/10 Entry $0.9914 to $0.9500 Now $0.8230 −16.99% ▼ −4.18% −5.49% vs SPY
- May 14, 202626w ago 8-K Neutral 5/10 Entry $1.03 to $0.9690 Now $0.8230 −20.10% ▼ −5.92% −8.04% vs SPY
- Mar 11, 202635w ago 8-K Mixed 7/10 Entry $1.15 to $1.13 Now $0.8230 −28.43% ▼ −1.74% −3.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers